Highlights

  • Percheron Therapeutics shares fell 11.11% to AUD 0.004 on 14 April 2026, extending yearly declines to 60%.
  • Company raised approximately AUD 2.2 million via entitlement and shortfall offers.
  • AUD 0.8 million raised from existing shareholders and AUD 1.4 million from new investors.
  • Funds to support development of HMBD-002 and progression toward Phase II trials.
  • New shares issued at AUD 0.005 with free-attaching options exercisable at AUD 0.01.
  • Total shares on issue increased to over 1.52 billion post-offer.

Percheron Therapeutics Ltd (ASX:PER) shares declined 11.11% to AUD 0.004 on 14 April 2026, extending a sharp 60% fall over the past year. The decline coincides with the company’s announcement of a completed capital raise, which, while strengthening its funding position, introduces dilution and reflects the typical pressures associated with early-stage biotechnology financing.

The update outlines the successful completion of a multi-part equity raising initiative aimed at advancing the company’s lead oncology program, HMBD-002, into its next phase of clinical development.

Company Overview: Focused on Oncology and Rare Disease Therapies

Percheron Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies targeting cancer and rare diseases. Its primary asset, HMBD-002, is a monoclonal antibody designed to target VISTA, an immune checkpoint regulator associated with tumour immune evasion.

The program has already completed a Phase I clinical trial in patients with advanced cancer, where it demonstrated a favourable safety and tolerability profile. The company is now working toward progressing the program into a Phase II clinical trial, expected in calendar year 2026.

As a pre-revenue biotech company, Percheron relies on external funding to support ongoing research, clinical trials, and operational activities.

$2.2 Million Capital Raise Completed with Strong Participation

The company confirmed it has successfully completed a 2-for-5 non-renounceable entitlement offer, first announced on 16 March 2026. The offer allowed eligible shareholders to subscribe for new shares at an issue price of AUD 0.005 per share.

Each two new shares issued also included one free-attaching unlisted option, exercisable at AUD 0.01 and expiring two years from the date of issue.

The capital raising process included both the entitlement offer and a shortfall offer, which made any unsubscribed securities available to existing shareholders and third-party investors.

In total, the company raised approximately AUD 2.2 million before costs:
• Around AUD 0.8 million was raised from eligible shareholders
• Approximately AUD 1.4 million was secured from new investors through the shortfall offer

The strong participation meant that all shortfall applications were fully allocated.

Expanded Capital Base Following Offer Completion

As a result of the capital raising, Percheron’s issued capital base has expanded significantly.

Prior to the offer, the company had approximately 1.09 billion shares on issue. Following the entitlement and shortfall offers, total shares on issue increased to approximately 1.52 billion.

In addition, the number of options on issue rose to over 406.9 million, reflecting the issuance of free-attaching options and additional options allocated to joint lead managers.

The entitlement offer contributed over 108.2 million new shares and 54.1 million options, while the shortfall offer added approximately 326.8 million shares and 163.4 million options.

This expanded capital structure reflects the scale of the funding round and is a key factor influencing investor sentiment in the short term.

Funding to Support Advancement of HMBD-002 Program

The company indicated that proceeds from the capital raise will be directed toward advancing the development of HMBD-002.

Management highlighted that the funding positions the company to make meaningful progress, particularly as it prepares for a Phase II clinical trial targeted for CY2026.

The program remains central to Percheron’s strategy, representing its primary pathway toward potential commercialisation.

The company also noted that the successful raise strengthens its ability to execute upcoming milestones and clinical development plans.

Upcoming Scientific Presentations Signal Development Progress

As part of its next steps, Percheron outlined plans to present clinical and preclinical data at major international oncology conferences.

The company is scheduled to present Phase I clinical trial data for HMBD-002 at the American Association for Cancer Research Annual Meeting in San Diego, taking place from 17 to 22 April 2026.

In addition, new preclinical data from a collaboration with QIMR Berghofer will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, scheduled from 29 May to 2 June 2026.

These presentations are expected to provide further insights into the therapeutic potential of HMBD-002 and support ongoing development efforts.

Offer Structure and Timeline Details

The entitlement offer provided shareholders with the opportunity to participate on a proportional basis, acquiring two new shares for every five existing shares held as of the record date.

Any securities not taken up through this process were subsequently offered under the shortfall offer, which attracted participation from both existing shareholders and new investors.

The allotment of new shares and options to eligible shareholders is scheduled for 15 April 2026, while placement of shortfall securities is expected to be completed by 22 April 2026.

Trading of the new shares is expected to commence on a normal settlement basis from 16 April 2026. The newly issued shares will rank equally with existing shares on issue.

What This Means for Investors?

The latest update from Percheron Therapeutics reflects a common dynamic in the biotechnology sector — the need to secure funding to progress clinical development, balanced against the impact of dilution on existing shareholders.

The capital raise provides the company with additional resources to advance its lead program, HMBD-002, and continue its clinical development pathway.

At the same time, the significant increase in shares on issue and the discounted pricing of the new equity may weigh on the share price in the near term.

The share price decline on 14 April 2026 appears to reflect this balance, as investors assess both the benefits of strengthened funding and the implications of dilution.

Looking ahead, market attention is likely to focus on the company’s ability to deliver clinical milestones, including upcoming data presentations and progress toward Phase II trials.